^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Regimen: (5-fluorouracil + cisplatin + docetaxel)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    10/11/2019
    Excerpt:
    Docetaxel Injection is a microtubule inhibitor indicated for...Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Docetaxel Teva in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    Pan-Asian adaptation of the EHNSeESMOeESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck

    Excerpt:
    Recommendation 3: Treatment...induction chemotherapy with TPF (up to three courses according to response) followed by RT alone is a validated treatment option [I, A].